Oncology Nursing Drug Handbook
In-app purchases
1K+
Downloads
Everyone
info
About this app
Written especially for nurses caring for patients with cancer, the Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation. Updated annually, this essential reference provides valuable information on effective symptom management, patient education, and chemotherapy administration.
Completely revised and updated, the Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs.
New drugs include:
apalutamide (Erleada™)
calaspargase pegol-mknl (Asparlas™)
Daunorubicin and cytarabine liposome for injection (Vyxeos®)
glucarpidase (Voraxaze®)
alpelisib (Piqray®)
binimetinib (Mektovi®)
dacomitinib (Vizimpro®)
Duvelisib (Copiktra®)
encorafenib (Braftovi®)
erdafitinib (Balversa™)
lorlatinib (Lorbrena®)
anakinra (Kineret®)
baricitinib (Olumiant®)
sarilumab (Kevzara®)
aprepitant injectable emulsion (Cinvanti®)
granisetron hydrochloride extended-release injection (Sustol®)
letermovir (Prevymis™)
omadacycline (Nuzyra™)
meropenem/vaborbactam (Vabomere™)
Plazomicin (Zemdri™)
baloxavir marboxil (Xofluza™)
imipenem/cilastatin sodium/relebactam (Recarbrio™)
eravacycline (Xerava™)
delafloxacin (Baxdela™)
Completely revised and updated, the Oncology Nursing Drug Handbook includes separate chapters on molecular and immunologic/biologic targeted therapies. These chapters provide fundamental reviews to assist nurses in understanding the cellular communication pathways disrupted by cancer. It also offers simplified content, attention to understanding the immune checkpoint inhibitors, new information about immunotherapy, new drugs and their indications, and updated indications and side effects for recently FDA approved drugs.
New drugs include:
apalutamide (Erleada™)
calaspargase pegol-mknl (Asparlas™)
Daunorubicin and cytarabine liposome for injection (Vyxeos®)
glucarpidase (Voraxaze®)
alpelisib (Piqray®)
binimetinib (Mektovi®)
dacomitinib (Vizimpro®)
Duvelisib (Copiktra®)
encorafenib (Braftovi®)
erdafitinib (Balversa™)
lorlatinib (Lorbrena®)
anakinra (Kineret®)
baricitinib (Olumiant®)
sarilumab (Kevzara®)
aprepitant injectable emulsion (Cinvanti®)
granisetron hydrochloride extended-release injection (Sustol®)
letermovir (Prevymis™)
omadacycline (Nuzyra™)
meropenem/vaborbactam (Vabomere™)
Plazomicin (Zemdri™)
baloxavir marboxil (Xofluza™)
imipenem/cilastatin sodium/relebactam (Recarbrio™)
eravacycline (Xerava™)
delafloxacin (Baxdela™)
Updated on
Safety starts with understanding how developers collect and share your data. Data privacy and security practices may vary based on your use, region, and age. The developer provided this information and may update it over time.
No data shared with third parties
Learn more about how developers declare sharing
This app may collect these data types
App activity, App info and performance, and Device or other IDs
Data is encrypted in transit
Data can’t be deleted
What's new
Updated data
Framework improvements
Framework improvements
